4,6-Dichloro-2-Methylpyrimidine CAS 1780-26-3 Purity ≥99.5% (GC) Pabrik Hot Sale
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
Ngaran Kimia | 4,6-Dichloro-2-Methylpyrimidine |
sinonim | 2-Metil-4,6-Dichloropyrimidine;2,4-Dichloro-6-Methylpyrimidine |
Nomer CAS | 1780-26-3 |
Nomer CAT | RF-PI687 |
Status Saham | Dina Stok, Skala Produksi Nepi ka Ton |
Formula Molekul | C5H4Cl2N2 |
Beurat Molekul | 163.00 |
Titik Lebur | 41,5 ~ 45,5 ℃ (lit.) |
Kalarutan (leyur dina) | Métanol |
merek | Kimia Ruifu |
Barang | spésifikasi |
Penampilan | Bubuk Kristal bodas atanapi Pareum-Bodas |
Kamurnian / Métode Analisis | ≥99,5% (GC) |
Leungitna dina Drying | ≤0,50% |
Résidu on Ignition | ≤0,20% |
Najis Tunggal | ≤0,50% |
Total Kotoran | ≤0,50% |
Standar tés | Standar Perusahaan |
Pamakéan | Panganteur Farmasi;Dasatinib / Moxonidine panengah |
4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) Prosés Rute
Bungkusan: Botol, kantong Aluminium foil, 25kg / Karton Drum, atawa nurutkeun sarat customer urang
Kaayaan Panyimpenan:Simpen dina wadah anu disegel dina tempat anu tiis sareng garing;Ngajaga tina cahaya sareng Uap
4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) dipaké dina sintésis antara farmasi jeung API.Produk Persiapan: Moxonidine (CAS: 75438-57-2);Dasatinib (CAS: 302962-49-8);Dasatinib Monohydrate (CAS: 863127-77-9);4-Chloro-2,6-Dimethylpyrimidine (CAS: 4472-45-1);4-Amino-6-Chloro-2-Methylpyrimidine (CAS: 1749-68-4).Moxonidine mangrupikeun jinis ubar antihipertensi énggal, anu biasa dianggo dina pengobatan hipertensi penting.Dibandingkeun sareng antihipertensi akting sentral anu langkung lami, Moxonidine ngiket sareng afinitas anu langkung ageung kana reséptor imidazoline I1 tibatan reséptor α2.Dasatinib mangrupikeun inhibitor kinase onkogenik lisan anu kuat, anu tiasa meungpeuk sinyal akselerasi réplikasi sél kanker, dina Méi 2009, Administrasi Pangan sareng Narkoba AS (FDA) sacara resmi disatujuan penjualan dasatinib, parantos dianggo sacara klinis pikeun pengobatan rupa-rupa kronis. leukemia myeloid (CML), kaasup pengobatan leukemia myeloid kronis nu tahan atawa teu toleran kana program perlakuan kaasup imatinib mesylate., Philadelphia kromosom-positip lymphoblastic leukemia akut (Ph + ALL) jeung pengobatan penderita tumor padet.